Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs Obinutuzumab plus Bendamustine in Follicular Lymphoma
NCT03492775Phase 2Completed
- Start
- Dec 2017
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obinutuzumab in follicular lymphoma (FL). Started Dec 2017; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03492775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492775.